Study Finds DMT Induces Trip Similar to Near Death Experience
There have long been anecdotal similarities between Near-Death Experiences (NDEs) and psychedelic trips induced by Dimethyltryptamine, or DMT. Within these experiences there are uncanny parallels, including out-of-body-experiences, traveling down a tunnel toward a white light, meetings with extra-dimensional or divine entities, and a feeling of being at peace. Then upon return to reality, there is often an overwhelming sense of gratitude for simply being alive that lingers indefinitely.
And now a study conducted at London’s Imperial College has been the first to scientifically compare these resemblances.
The study, which was headed by the young impresario of the university’s Psychedelic Research Group, Robin Carhart-Harris, administered DMT intravenously to 13 participants who had prior experience using psychedelics ranging from DMT, to psilocybin and LSD.
Two traits the study tested were the commonly reported ego-dissolution and the mystical or religious experience. To qualify these highly subjective experiences, they used two standardized tests created by colleagues: The Mystical Experience Questionnaire and the Validation of the Ego-Dissolution Inventory (EDI).
In their experiment, Carhart-Harris and colleagues administered a range of doses to participants in a single-blind study over two sessions, of which one session only a placebo was given.
Their results showed that every participant rated their DMT experience above the conventional cutoff for an NDE, essentially ranking the DMT trip higher than the minimum level one might consider an experience to be an NDE. They concluded, “results show that near-death experience phenomena were significantly enhanced following DMT administration.”
Watch this episode of Psychedelica in which we explore the scientific studies being conducted with DMT: The Spirit Molecule:
The theme of death and rebirth is also rife within the ayahuasca experience. The names of the plants used to create the ayahuasca brew contain references to death, while the word ayahuasca translates to ‘vine of the dead’ or ‘vine of the soul.
Not so surprisingly, when Raymond Moody coined the phrase “Near-Death Experience” in 1975, he actually noted the comparisons between NDEs and DMT trips. Today, after four decades of clinical research and a relaxation of certain taboos, the study of DMT has revealed it is an endogenous chemical, produced in varying quantities in the lungs and in cerebral spinal fluid.
When the DMT molecule was studied in a lab by Dr. Rick Strassman – head of the first clinical study to administer DMT in the United States – he found that it minimized neuronal damage from hypoxia, a lack of oxygen in the brain. This discovery led Strassman to entertain the idea that maybe the body releases DMT in emergency situations when the brain’s oxygen supply is dwindling, producing the psychedelic NDE. Could this explain the similarities?
Watch Dr. Raymond Moody discuss Near Death Experiences on this episode of Beyond Belief:
About the Author
New Studies Find Psychedelics Highly Effective for Alcoholism
New studies show unprecedented success in the treatment of alcoholism with psychedelic therapy.
The psychedelic revolution in mental health has produced overwhelming scientific evidence demonstrating the great efficacy of psychedelics in the treatment of various mental health disorders. Now, several new studies involving the drugs ketamine and MDMA are showing significant promise in the treatment of alcoholism.
Dr. Ben Sessa is a psychiatrist and chief medical officer at Awakn Life Sciences, an English biotech company that is at the forefront of the research, development, and delivery of psychedelic medicines.
The company is especially focused on the treatment of Alcohol Use Disorder or AUD, given how prevalent and challenging it is to treat.
“Alcoholism is a huge public health problem. It’s also a psychiatric condition that’s very poorly treated with very poor outcomes with traditional methods,” Sessa said. “Relapse to drinking after getting dry is around 80 to 90 percent at 12 months. That’s an embarrassingly poor statistic. Psychedelics offer a completely new approach; they offer the patient to explore the root causes of addiction, which so often is trauma. Psychedelic-assisted psychotherapy is an intensive upfront piece of work that gets the patient better, so they don’t have to keep coming back. It is a completely different paradigm shift to the way we currently manage patients in maintenance therapies.”
A recent study conducted by researchers at the University of Exeter and Awakn Life Sciences is the world’s first to examine the use of ketamine to treat AUD in a randomized controlled trial.
“Ketamine is a very well-established human medicine. It is indeed the only psychedelic that’s licensed as a medicine, as an anesthetic medicine, and has been used since the 60s as such. It’s an incredibly safe medicine. When it’s used at a much lower dose, it produces an altered state of consciousness. What we do in psychedelic-assisted psychotherapy with ketamine, is we use this altered state of consciousness to affect a more effective and deeper form of psychotherapy. So, we’re using ketamine as an adjunct to psychotherapy to treat addictions,” he said.
